ArticleDrug delivery2017
A green approach to dual-drug nanoformulations with targeting and synergistic effects for cancer therapy.
Article in Drug delivery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Polymer Nanoparticles Advancements for Gynecological Cancers.International journal of nanomedicine · 2025Review
- Drug self-delivery systems: A comprehensive review on small molecule nanodrugs.BioImpacts : BI · 2025Review
- A nanoscale natural drug delivery system for targeted drug delivery against ovarian cancer: action mechanism, application enlightenment and future potential.Frontiers in immunology · 2024Review
- The Use of Nanoneedles in Drug Delivery: an Overview of Recent Trends and Applications.AAPS PharmSciTech · 2023Review
- Carrier-free nanodrugs with efficient drug delivery and release for cancer therapy: From intrinsic physicochemical properties to external modification.Bioactive materials · 2022Review
- Advances in Antitumor Nano-Drug Delivery Systems of 10-Hydroxycamptothecin.International journal of nanomedicine · 2022Review
- Study on the Application of Doxorubicin-Loaded Magnetic Nanodrugs in Targeted Therapy of Liver Cancer.Applied bionics and biomechanics · 2022Article
- Dual Drug Loaded, pH-Sensitive Metal-Organic Particles for Synergistic Cancer Therapy.Frontiers in bioengineering and biotechnology · 2022Article
- Development of a pH-sensitive functionalized metal organic framework:RSC advances · 2021Article
- Evaluating the Anticarcinogenic Activity of Surface Modified/Functionalized Nanochitosan: The Emerging Trends and Endeavors.Polymers · 2021Review
- Chitosan nanoparticles as a promising tool in nanomedicine with particular emphasis on oncological treatment.Cancer cell international · 2021Review
- Multifunctional Cargo-Free Nanomedicine for Cancer Therapy.International journal of molecular sciences · 2018Review
- Dual-responsive dithio-polydopamine coated porous CeOInternational journal of nanomedicine · 2018Article
- Polydopamine and peptide decorated doxorubicin-loaded mesoporous silica nanoparticles as a targeted drug delivery system for bladder cancer therapy.Drug delivery · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exploration of efficient dual-drug nanohybrids, particularly those with high drug loading, specific targeting property, and long-termed stability, is of highly importance in cancer therapy. A pH-driven coprecipitation was performed in the aqueous phase to obtain a dual-drug nanoformulation, composed of 10-hydroxycamptothecine (HCPT) nanoneedles integrated with an exterior thin layer of the methotrexate (MTX)-chitosan conjugate. The high stability of nanohybrids in water and the targeting property provided by the MTX ingredient function synergistically to the prolonged and sustained drug release property in tumor tissues and the increased cellular uptake. The cytotoxicity test illustrates that dual-drug nanoneedles possess the remarkable killing ability to HeLa cells with the combination index at 0.33 ± 0.07. After cellular internalization, the release of both drug ingredients results in an excellent anticancer activity in vivo with the minimized adverse side effects. Design of a green approach to the carrier-free, dual-drug nanoformulations enables to develop emerging drug delivery systems for cancer diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.